Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
10
-
Shares change
-
-33K
-
Total reported value, excl. options
-
$54.00
-
Value change
-
-$84.5K
-
Number of sells
-
-3
-
Price
-
$5.40
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q4 2023
9 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q4 2023.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10 shares
of 18.4M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include CITADEL ADVISORS LLC (12.9K shares), MORGAN STANLEY (1.45K shares), JPMORGAN CHASE & CO (25 shares), Kozak & Associates, Inc. (10 shares), VANGUARD GROUP INC (0 shares), Qube Research & Technologies Ltd (0 shares), Tower Research Capital LLC (TRC) (0 shares), CITADEL ADVISORS LLC (2.3K shares), CITADEL ADVISORS LLC (1.3K shares), and Wellington Shields Capital Management, LLC (133K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.